Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 20;32(6):579-86.
doi: 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21.

Liquid biopsies: genotyping circulating tumor DNA

Luis A Diaz Jr  1 , Alberto Bardelli
Affiliations
Review

Liquid biopsies: genotyping circulating tumor DNA

Luis A Diaz Jr et al. J Clin Oncol. .

Abstract

Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these sequence alterations are highly informative, sampling tumor tissue has significant inherent limitations; tumor tissue is a single snapshot in time, is subject to selection bias resulting from tumor heterogeneity, and can be difficult to obtain. Cell-free fragments of DNA are shed into the bloodstream by cells undergoing apoptosis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and prognosis. Moreover, recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of cfDNA for somatic genomic alterations found in tumors. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Methodologies for detecting circulating tumor DNA (ctDNA). Sanger sequencing (dideoxy-terminator sequencing), amplification refractory mutation system (ARMS),, pyrosequencing, pyrophosphorolysis-activated polymerization (PAP), tagged-amplicon deep sequencing (TAM-Seq), digital polymerase chain reaction (PCR), and beads, emulsion, amplification, and magnetics (BEAMing).
Fig 2.
Fig 2.
Genetic alterations detectable in circulating cell-free tumor DNA. Tumor cells release small fragments of cell-free DNA into circulation by multiple mechanisms. Cancer-associated genetic alterations such as point mutations, copy number variations, chromosomal rearrangements, and methylation patterns can be detected in circulating cell-free DNA.
Fig 3.
Fig 3.
Detection of tumor-specific DNA mutations in the blood of patients to monitor response and relapse with targeted therapies. This schematic depicts a representation of a patient with metastatic colorectal cancer. At the time of presentation, DNA from the primary tumor is used to identify the baseline mutation profile; in this case, the tumor is found to be APC mutant and KRAS wild type (WT). At baseline, evaluation of the patient's plasma DNA only identifies KRAS WT fragments. This patient is treated with an anti–epidermal growth factor receptor (EGFR) monoclonal antibody, experiences a clinical response, and has a corresponding decrease in APC mutation level, further indicating a decrease in tumor burden. Continuous monitoring of plasma DNA shows the emergence of KRAS and NRAS mutations and/or MET amplification, indicative of the emergence of multiple different resistance clones. Clinical resistance becomes manifest at a later time point. Test tubes represent samples of plasma from which circulating free DNA is extracted and used to monitor the presence of cancer-specific aberrations.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mandel P, Metais P: Les acides nucleiques du plasma sanguin chez l'homme [in French] C R Seances Soc Biol Fil 142:241–243,1948 - PubMed
    1. Lo YM, Chiu RW: Genomic analysis of fetal nucleic acids in maternal blood Annu Rev Genomics Hum Genet 13:285–306,2012 - PubMed
    1. Lo YM Corbetta N Chamberlain PF, etal: Presence of fetal DNA in maternal plasma and serum Lancet 350:485–487,1997 - PubMed
    1. Lo YM Hjelm NM Fidler C, etal: Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma N Engl J Med 339:1734–1738,1998 - PubMed
    1. Papageorgiou EA Karagrigoriou A Tsaliki E, etal: Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21 Nat Med 17:510–513,2011 - PMC - PubMed

Publication types